Latest Blogs, Articles, and More View More >>
Seeing Red
BY MICHAEL A. POSTOW
Rash is the most common side effect of cancer immunotherapies, but patients should watch for more serious issues.
Avastin After Recurrence in Glioblastoma Shows No Benefit
BY BRIDGET M. KUEHN
Continuing Avastin (bevacizumab) in patients with recurrent glioblastoma after progression of the disease does not improve patient outcomes, according to results from the phase 2 CABARET trial.
IDH Mutation Status May Guide Therapy in Patients With High-Risk Low-Grade Glioma
BY STAFF WRITER
An analysis of three interrelated biomarkers in high-risk low-grade glioma (LGG) has identified distinct risk groups by isocitrate dehydrogenase (IDH) mutation status and suggested appropriate treatment strategies.
Defiantly Alive
BY SUSAN FARISS
If demanding to be involved in treatment decisions is considered defiant, I'll be defiantly alive.
Into the Future
BY SUSAN KREIMER
For some with lung cancer, immunotherapies are sparking long-lasting responses.
Cancer and Chemo Side Effects: I Am Fortunate and Tainted
BY BARBARA TAKO
A grumpy and grateful cancer survivor reflects on her neuropathy and lymphedema.
Sweet and Vicious: Sugar and Sugar Substitutes
BY AMANDA BONTEMPO
Sugar does not feed cancer cells any differently than it feeds healthy cells.
View More >>
Special Feature
ShareYourStory
$auto_registration$